Bitter pill for pharmaceutical companies
March 28 2005 – Financial Times By Vitaliy Katsenelson, CFA In the good old days, pharmaceutical companies traded at a significant premium to the market, which was justified by predictable earnings growth, bulletproof balance sheets, Microsoft-monopoly-like profit margins and a return on investment that was the envy of corporate America. Political and drug [...]